Phase II trial of adjuvant pelvic radiation “sandwiched” between ifosfamide or ifosfamide plus cisplatin in women with uterine carcinosarcoma
Einstein MH, Klobocista M, Hou JY, Lee S, Mutyala S, Mehta K, Reimers LL, Kuo D, Huang GS, Goldberg GL. Phase II trial of adjuvant pelvic radiation “sandwiched” between ifosfamide or ifosfamide plus cisplatin in women with uterine carcinosarcoma. Gynecologic Oncology 2011, 124: 26-30. PMID: 22055846, PMCID: PMC3787514, DOI: 10.1016/j.ygyno.2011.10.008.Peer-Reviewed Original ResearchConceptsDisease-free survivalAddition of cisplatinUterine carcinosarcomaResidual diseasePelvic external beam radiotherapyYear disease-free survivalKaplan-Meier statistical methodAdjuvant pelvic radiationGrade 3/4 neutropeniaGross residual diseaseIfosfamide/cisplatinPhase II trialStage 1 patientsTolerable toxicity profileRare uterine tumorExternal beam radiotherapyAdjuvant settingEfficacious regimenGOG trialsPelvic radiationRecurrent carcinosarcomaMedian followSystemic chemotherapyII trialUterine tumors